论文部分内容阅读
目的观察我市注射用头孢哌酮钠舒巴坦钠不良反应的发生情况,为临床合理用药提供指导。方法回顾性分析2010—2012年贺州地区注射用头孢哌酮钠舒巴坦钠不良反应/事件(ADR/ADE)报告160例,统计分析不良反应特征。结果①男性100例(62.5%),女性60例(37.5%),男性多于女性;≤14岁者55例(34.4%),≥50岁者56例(35.0%),以儿童及老年人居多;原发病主要以呼吸系统为主,80例(50.0%)。②不良反应发生时间主要集中在用药3d内,严重不良反应主要集中在用药1h内;主要为过敏反应,其中皮肤及其附件损害者94例次(94/170,55.29%),全身性损害32例(18.8%)。③主要上报单位为市/县级二等医院149例(93.1%),以一般不良反应为主,148例(148/160,92.5%),采取治疗措施后治愈59例(36.9%),好转101例(63.1%)。结论注射用头孢哌酮钠舒巴坦钠的主要不良反应为过敏反应,应加强对二级医疗机构的用药监控,尤其是对儿童和老年呼吸系统疾病患者,杜绝药物滥用,提高用药的安全性。
Objective To observe the incidence of cefoperazone sodium and sulbactam sodium for injection in our city and provide guidance for clinical rational drug use. Methods A retrospective analysis of 160 cases of cefoperazone sodium / sulbactam sodium adverse reactions / events (ADR / ADE) injection in Hezhou area during 2010-2012 was conducted, and the characteristics of adverse reactions were statistically analyzed. Results ① There were 100 males (62.5%) and 60 females (37.5%), more males than females; 55 (34.4%) ≤14 and 56 (35.0%) ≥50, Mostly; primary disease mainly respiratory system, 80 cases (50.0%). The time of adverse reactions mainly concentrated in medication 3d, the serious adverse reactions mainly concentrated in medication 1h; mainly allergic reactions, including 94 cases of skin and its accessory damage (94 / 170,55.29%), systemic damage 32 Example (18.8%). The main reporting units were 149 cases (93.1%) of the municipal / county-level second-class hospitals with 148 cases (148/160%, 92.5%) as the main adverse reactions and 59 cases (36.9%) after the treatment measures were cured, 101 cases (63.1%). Conclusions The main adverse reaction of cefoperazone sodium and sulbactam sodium for injection is allergic reaction. The monitoring of drug use in secondary medical institutions should be strengthened, especially in children and elderly patients with respiratory diseases, so as to eliminate drug abuse and improve the safety of medication.